Robert Fucigna, MD
Ophthalmology · Stamford, CTNPI 1841204997
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,098 of the $3,458 with a category attached, or 60.7%. 16 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 50.0% of the total. Reporting peaked in 2019 at $1,787 and has fallen 70.2% since, to $532 in 2025.
Across 47 payments — averaging $73.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Glaukos Corporation$328
- Sun Pharmaceutical Industries Inc.$287
- Bausch & Lomb Americas Inc.$207
- Carl Zeiss Meditec USA, Inc.$182
- Tarsus Pharmaceuticals, Inc.$169
- plus $558 from 10 others
What the payments were for
- Travel & lodging$1,28037%
- Food & beverage$2,09861%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 8 | $1,728 |
| Glaukos Corporation | 2 | $328 |
| Sun Pharmaceutical Industries Inc. | 10 | $287 |
| Bausch & Lomb Americas Inc. | 4 | $207 |
| Carl Zeiss Meditec USA, Inc. | 2 | $182 |
| Tarsus Pharmaceuticals, Inc. | 3 | $169 |
| AbbVie(2 entities) | 6 | $167 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $139 |
| Aerie Pharmaceuticals, Inc. | 1 | $119 |
| Oyster Point Pharma, Inc. | 2 | $29 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Johnson & Johnson Vision Care, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Ivantis, Inc | 1 | $16 |
| Alcon | 1 | $16 |
| Harrow Eye, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,574
- Tecnis 3-piece IOL$1,574
- Tecnis Symphony IOL$1,574
- Tecnis Symphony Toric IOL$1,574
- QUATERA 700$159
- CEQUA$125
- MIEBO$125
- XIIDRA$125
- XDEMVY$125
- iDoseTR$122
- Rhopressa$119
- Rocklatan$119
- ULTRA MULTIFOCAL TORIC$102
How this compares
$3,458 in reported general payments places this provider in the 80th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 28 | $21,300 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $11,869 |
| Alphagan PBrimonidine Tartrate | 17 | $11,806 |
| Prednisolone Acetate | 68 | $2,960 |
| Timolol Maleate | 70 | $2,124 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 12 | $1,607 |
| Latanoprost | 196 | $1,599 |
| Gentamicin Sulfate | 79 | $607 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 65 | $596 |
| Ketorolac Tromethamine | 27 | $579 |
| ErythromycinErythromycin Base | 62 | $424 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $341 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $287 |
| Dorzolamide Hcl | 31 | $285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Alphagan P | $167 | $44,97475 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Stamford
- Gregory GallousisStamford$10K
- Lauren SchneiderStamford$4K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.